Edition:
India

GBT Says FDA Agrees To Review Sickle Cell Drug Under Accelerated Pathway


Monday, 3 Dec 2018 

Dec 3 (Reuters) - Global Blood Therapeutics Inc ::GBT ANNOUNCES U.S. FDA AGREES WITH ITS PROPOSAL RELATING TO ACCELERATED APPROVAL PATHWAY FOR VOXELOTOR FOR THE TREATMENT OF SICKLE CELL DISEASE AND GBT PLANS TO SUBMIT NEW DRUG APPLICATION (NDA).GLOBAL BLOOD THERAPEUTICS INC - PRE-NDA MEETING TO BE REQUESTED FOR Q1 OF 2019. 

Company Quote

57.49
0.98 +1.73%
1:30am IST